EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Glutathione-S-Transferase Theta 2 (GSTT2) Modulates the Response to Bacillus Calmette–Guérin Immunotherapy in Bladder Cancer Patients

Juwita N Rahmat iD, Sin Mun Tham iD, Ting Li Ong iD, Yew Koon Lim iD, Mugdha Vijay Patwardhan iD, Lata Raman Nee Mani, Revathi Kamaraj iD, Yiong Huak Chan iD, Tsung Wen Chong iD, Edmund Chiong, Kesavan Esuvaranathan iD, Ratha Mahendran iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25168947 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Juwita N Rahmat und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, Singapore. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Glutathione Transferase, BCG Vaccine, Immunotherapy. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National University Health System, Joseph Lim Boon Tiong Urology Cancer Research Initiative.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glutathione-S-transferases (GST) enzymes detoxify xenobiotics and are implicated in response to anticancer therapy. This study evaluated the association of GST theta 1 (GSTT1), GSTT2, and GSTT2B with Mycobacterium bovis Bacillus Calmette–Guérin (BCG) response in non-muscle-invasive bladder cancer treatment. In vitro assessments of GSTT2 knockout (KO) effects were performed using cell lines and dendritic cells (DCs) from GSTT2KO mice. Deletion of GSTT2B, GSTT1, and single-nucleotide polymorphisms in the promoter region of GSTT2 was analysed in patients (n = 205) and healthy controls (n = 150). Silencing GSTT2 expression in MGH cells (GSTT2BFL/FL) resulted in increased BCG survival (p < 0.05) and decreased cellular reactive oxygen species. In our population, there are 24.2% with GSTT2BDel/Del and 24.5% with GSTT2BFL/FL. With ≤ 8 instillations of BCG therapy (n = 51), 12.5% of GSTT2BDel/Del and 53.8% of GSTT2BFL/FL patients had a recurrence (p = 0.041). With ≥9 instillations (n = 153), the disease recurred in 45.5% of GSTT2BDel/Del and 50% of GSTT2BFL/FL. GSTT2FL/FL patients had an increased likelihood of recurrence post-BCG therapy (HR 5.5 [1.87–16.69] p < 0.002). DCs from GSTT2KO mice produced three-fold more IL6 than wild-type DCs, indicating a robust inflammatory response. To summarise, GSTT2BDel/Del patients respond better to less BCG therapy and could be candidates for a reduced surveillance regimen.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsGlutathione TransferaseBCG VaccineImmunotherapyHumansAnimalsMiceFemaleMaleAgedMiddle AgedPolymorphism, Single NucleotideCell Line, TumorDendritic CellsMice, KnockoutMycobacterium bovis

Stichwörter der Autor:innen

BCG vaccinebladder cancergeneticglutathione S-transferase theta 2immunotherapypolymorphismurinary bladder neoplasms

Substanzen

Glutathione TransferaseBCG Vaccineglutathione S-transferase T1

Autor:innen und Institutionen

  • Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, Singapore.
  • School of Engineering, Biomedical Engineering, Temasek Polytechnic, Singapore 529757, Singapore.
  • Biostatistics Unit, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, Singapore.
  • Department of Urology, Singapore General Hospital, Singapore 169608, Singapore.
  • Division of Surgery & Surgical Oncology, National Cancer Center Singapore, Singapore 168583, Singapore.
  • Department of Urology, National University Hospital, National University Health System, Singapore 119074, Singapore.

ORCID-Profile: Juwita N Rahmat, Sin Mun Tham, Ting Li Ong, Yew Koon Lim, Mugdha Vijay Patwardhan, Revathi Kamaraj, Yiong Huak Chan, Tsung Wen Chong, Kesavan Esuvaranathan, Ratha Mahendran

Förderung

  • National University Health System
  • Joseph Lim Boon Tiong Urology Cancer Research Initiative

Zitieren

APA

Rahmat, J. N., Tham, S. M., Ong, T. L., Lim, Y. K., Patwardhan, M. V., Nee Mani, L. R., Kamaraj, R., Chan, Y. H., Chong, T. W., Chiong, E., Esuvaranathan, K., & Mahendran, R. (2024). Glutathione-S-Transferase Theta 2 (GSTT2) Modulates the Response to Bacillus Calmette–Guérin Immunotherapy in Bladder Cancer Patients. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25168947

Vancouver

Rahmat JN, Tham SM, Ong TL, Lim YK, Patwardhan MV, Nee Mani LR, et al. Glutathione-S-Transferase Theta 2 (GSTT2) Modulates the Response to Bacillus Calmette–Guérin Immunotherapy in Bladder Cancer Patients. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25168947

BibTeX
@article{Rahmat2024,
  author = {Rahmat, Juwita N and Tham, Sin Mun and Ong, Ting Li and Lim, Yew Koon and Patwardhan, Mugdha Vijay and Nee Mani, Lata Raman and Kamaraj, Revathi and Chan, Yiong Huak and Chong, Tsung Wen and Chiong, Edmund and Esuvaranathan, Kesavan and Mahendran, Ratha},
  title = {Glutathione-S-Transferase Theta 2 (GSTT2) Modulates the Response to Bacillus Calmette–Guérin Immunotherapy in Bladder Cancer Patients},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25168947}
}
Kostenlos starten →